The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticoster...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2016-12, Vol.63 (11), p.1490-1493
Main Authors: Del Castillo, Maria, Romero, Fabian A., Argüello, Esther, Kyi, Chrisann, Postow, Michael A., Redelman-Sidi, Gil
Format: Article
Language:English
Subjects:
Adolescent
Adrenal Cortex Hormones - adverse effects
Adrenal Cortex Hormones - therapeutic use
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
BRIEF REPORTS
Cell Cycle Checkpoints
Child
Child, Preschool
Female
Humans
Immune system
Immunologic Factors - administration & dosage
Immunologic Factors - therapeutic use
Immunotherapy - adverse effects
Infection - epidemiology
Infection - etiology
Infection - microbiology
Infection - virology
Infliximab - adverse effects
Infliximab - therapeutic use
Male
Medical Records
Melanoma
Melanoma - complications
Melanoma - drug therapy
Melanoma - microbiology
Middle Aged
Molecules
Retrospective Studies
Risk Factors
Spectrum analysis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciw539